当前位置:药药网 / 数据中心 /变体注释摘要_体外和功能分析类型
“布呋洛尔”、“右美沙芬”-"bufuralol","dextromethorphan"
变量_单倍型
CYP2D6*1, CYP2D6*17
药物名称(英)
"bufuralol","dextromethorphan"
记事
The *17 construct (T107I, R296C and S486T) was expressed in cos-7 cells and the kinetic parameters Km and Vmax were determined for dextromethorphan and bufuralol compared to *1 construct. dextromethorphan: Km 2 fold increase to *1; Vmax 33% reduction. bufuralol: Km no effect compared to *1; Vmax 45% decrease compared to *1. Resulting in about 25 % (p<0.01) reduction in intrinsic clearance for dextromethorphan and 37% (p<0.02) for bufuralol for *17 compared to *1. CYP2D6 cDNA with *17=T105I, R296C; S486T variations. The intrinsic clearance for these substrates are also lower from *17 compared to *2 (p<0.05).
专家论述
CYP2D6 *17 is associated with decreased clearance of bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.